ArticleEndocrine connections2024

Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system.

Yankun Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.